Company Filing History:
1 out of 1,928 
1 out of 2,118 
1 Years Active: 2022
Title: Innovator Amit Golding: Pioneering Targeted Delivery Systems for Immunomodulators
Introduction: Amit Golding, based in Baltimore, MD, is an accomplished inventor recognized for his significant contributions to the field of biomedical engineering. With one patent to his name, he has developed a groundbreaking method for the targeted delivery of immunomodulators aimed at treating autoimmunity and cancer.
Latest Patents: His patent, titled "Self-assembled particles for targeted delivery of immunomodulators to treat autoimmunity and cancer," presents a novel framework for delivering therapeutic drugs through a polymeric system. This system encompasses a PEG-bl-PPS di-block polymer constructed in micelles, filomicelles, or polymersomes. The innovation focuses on effectively binding and interacting with specific cell types through shape-based targeting.
Career Highlights: Golding has had a distinguished career, working extensively in esteemed institutions such as the University of Maryland, Baltimore, and Northwestern University. His experience in both academia and research has equipped him with the necessary skills to innovate in the complex fields of immunology and cancer treatment.
Collaborations: Throughout his career, Golding has collaborated with notable experts, including Marilyn Allen and Evan A Scott. These partnerships have likely contributed to his research and innovation prowess, fostering an environment for collaborative scientific advancement.
Conclusion: Amit Golding's innovative approach to targeted drug delivery systems showcases a remarkable intersection of technology and medicine. His patent represents a significant stride in addressing the challenges of treating autoimmunity and cancer, paving the way for future advancements in the biomedical field.